VBLT Quote, Trading Chart, Vascular Biogenics Ltd.

$ Last:

Change Percent:

$ Open:

$ Previous Close:

$ High:

$ Low:

0 Volume:

01/01/1970 12:00:00 am Last Trade Date Time:

Quotes are delayed by 15 to 20 minutes.

Stock Date	Open Price	Close Price	High	Low	Volume
2021-02-25	1.97	1.82	1.981	1.77	1,573,241
2021-02-24	2.05	1.96	2.1	1.9	2,520,037
2021-02-23	2.73	2.06	3.17	1.92	27,101,798
2021-02-22	2.77	2.23	2.83	2.21	2,520,194
2021-02-19	2.48	2.55	2.55	2.47	252,840
2021-02-18	2.45	2.51	2.51	2.38	515,111
2021-02-17	2.57	2.52	2.57	2.4612	297,011
2021-02-16	2.63	2.58	2.717	2.55	540,287
2021-02-15	2.51	2.55	2.55	2.4263	316,746
2021-02-12	2.51	2.55	2.55	2.4263	314,559
2021-02-11	2.62	2.52	2.64	2.35	524,909
2021-02-10	2.33	2.6	2.64	2.33	1,226,149
2021-02-09	2.53	2.31	2.5819	2.17	2,002,315
2021-02-08	2.5	2.46	2.58	2.41	843,166
2021-02-05	2.35	2.39	2.43	2.25	465,632
2021-02-04	2.35	2.33	2.35	2.19	675,143
2021-02-03	2.38	2.29	2.4049	2.21	616,717
2021-02-02	2.5	2.39	2.5	2.32	296,083
2021-02-01	2.51	2.44	2.56	2.37	441,489
2021-01-29	2.43	2.49	2.59	2.31	687,724

Stock Information

Vascular Biogenics Ltd. Company Name:

VBLT Stock Symbol:

NASDAQ Market:

Get VBLT Alerts

News, Short Squeeze, Breakout and More Instantly...

VBLT - VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

TEL AVIV, Israel, Feb. 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer. The co...
VBLT - VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

TEL AVIV, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-...
VBLT - VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC

TEL AVIV, Israel, Jan. 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications, tod...